CASI Pharmaceuticals, Inc.

NasdaqCM:CASI Stok Raporu

Piyasa değeri: US$92.3m

CASI Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

CASI Pharmaceuticals CEO'su Wei-Wu He, Apr2019 tarihinde atandı, in görev süresi 5.58 yıldır. şirketin hisselerinin 5.07% doğrudan sahiptir ve bu hisselerin değeri $ 4.68M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.3 yıl ve 9.3 yıldır.

Anahtar bilgiler

Wei-Wu He

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi5.6yrs
CEO sahipliği5.1%
Yönetim ortalama görev süresi2.3yrs
Yönetim Kurulu ortalama görev süresi9.3yrs

Son yönetim güncellemeleri

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12
Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Sep 02
We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

May 20
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

CASI Pharmaceuticals Q2 2022 Earnings Preview

Aug 11

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

CEO Tazminat Analizi

Wei-Wu He'un ücretlendirmesi CASI Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023n/an/a

-US$27m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022n/an/a

-US$41m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$10mUS$322k

-US$37m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$819kUS$578k

-US$48m

Sep 30 2020n/an/a

-US$47m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$9mUS$424k

-US$46m

Sep 30 2019n/an/a

-US$43m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$32m

Dec 31 2018US$6mn/a

-US$27m

Sep 30 2018n/an/a

-US$23m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$781kn/a

-US$11m

Tazminat ve Piyasa: Wei-Wu şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Wei-Wu şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Wei-Wu He (59 yo)

5.6yrs

Görev süresi

US$9,665,359

Tazminat

Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Wei-Wu He
Chairman & CEO5.6yrsUS$9.67m5.07%
$ 4.7m
Alexander A. Zukiwski
Executive VP & Chief Medical Officer7.6yrsUS$1.18mVeri yok
Wei Zhang
Senior Vice Presidentless than a yearUS$2.56m0.013%
$ 12.4k
Daniel Lang
MD, Senior VP & Chief Financial Officerless than a yearVeri yokVeri yok
Chunhua Wang
Chief Operating Officer6.7yrsVeri yokVeri yok
Wei Gao
General Counsel1.8yrsVeri yokVeri yok
James E. Goldschmidt
Chief Business Development Officerno dataVeri yokVeri yok
Hai Huang
Global Chief Commercial Officer & GM of CASI Chinaless than a yearVeri yokVeri yok
Amanda Cui
VP & Global Controllerno dataVeri yokVeri yok
Kun Qian
VP & Global Controller2.8yrsVeri yokVeri yok

2.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: CASI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Wei-Wu He
Chairman & CEO12.8yrsUS$9.67m5.07%
$ 4.7m
Sue Eckhardt
Member of Scientific Advisory Board18.3yrsVeri yokVeri yok
Y. Alexander Wu
Independent Director11.6yrsUS$150.50kVeri yok
Thomas Folinsbee
Independent Directorno dataVeri yokVeri yok
Ghassan Abou-Alfa
Member of Clinical Advisory Board9.3yrsVeri yokVeri yok
Zhenbo Su
Independent Director1.7yrsVeri yokVeri yok
Robert Mayer
Member of Clinical Advisory Board9.3yrsVeri yokVeri yok
Xuebo Zeng
Independent Director8.8yrsVeri yokVeri yok

9.3yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CASI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).